3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
34
Doxorubicin
24
fludarabine phosphate
20
Vinblastine
20
Nivolumab
20
Dacarbazine
20
Brentuximab Vedotin
20
pembrolizumab
19
fludarabine
18
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
14
Filgrastim
13
Melphalan
12
Granulocyte Colony-Stimulating Factor
10
Gemcitabine
10
Bleomycin
10
Tacrolimus
9
Radiotherapy
9
Prednisone
9
Peripheral Blood Stem Cell Transplantation
9
Busulfan
9
Specimen Handling
8
Vincristine
7
Sirolimus
7
Magnetic Resonance Spectroscopy
7
Cyclosporine
7
pegfilgrastim
6
Stem Cell Transplantation
6
Bendamustine Hydrochloride
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
CLR1404
×
1 year
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled